Ignite Creation Date:
2024-05-06 @ 6:42 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05754853
Status:
RECRUITING
Last Update Posted:
2023-04-13
First Post:
2023-02-22
Brief Title:
A Study of MRG002 Versus Investigators Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Sponsor:
Shanghai Miracogen Inc
Organization:
Shanghai Miracogen Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-06
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-22
First Submit QC Date:
February 22 2023
Study First Post Date:
2023-03-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-12
Last Update Post Date:
2023-04-13
Last Update Post Date Type:
ACTUAL